PMID- 32053144
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20211218
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 116
IP  - 13
DP  - 2020 Nov 1
TI  - The impact of patient sex on the response to intramyocardial mesenchymal stem 
      cell administration in patients with non-ischaemic dilated cardiomyopathy.
PG  - 2131-2141
LID - 10.1093/cvr/cvaa004 [doi]
AB  - AIMS: Sex differences impact the occurrence, presentation, prognosis, and 
      response to therapy in heart disease. Particularly, the phenotypic presentation 
      of patients with non-ischaemic dilated cardiomyopathy (NIDCM) differs between men 
      and women. However, whether the response to mesenchymal stem cell (MSC) therapy 
      is influenced by sex remains unknown. We hypothesize that males and females with 
      NIDCM respond similarly to MSC therapy. METHODS AND RESULTS: Male (n = 24) and 
      female (n = 10) patients from the POSEIDON-DCM trial who received MSCs via 
      transendocardial injections were evaluated over 12 months. Endothelial function 
      was measured at baseline and 3 months post-transendocardial stem cell injection 
      (TESI). At baseline, ejection fraction (EF) was lower (P = 0.004) and 
      end-diastolic volume (EDV; P = 0.0002) and end-systolic volume (ESV; P = 0.0002) 
      were higher in males vs. females. In contrast, baseline demographic 
      characteristics, Minnesota Living with Heart Failure Questionnaire (MLHFQ), and 
      6-min walk test (6MWT) were similar between groups. EF improved in males by 6.2 
      units (P = 0.04) and in females by 8.6 units (P = 0.04; males vs. females, 
      P = 0.57). EDV and ESV were unchanged over time. The MLHFQ score, New York Heart 
      Association (NYHA) class, endothelial progenitor cell-colony forming units, and 
      serum tumour necrosis factor alpha improved similarly in both groups. CONCLUSION: 
      Despite major differences in phenotypic presentation of NIDCM in males and 
      females, this study is the first of its kind to demonstrate that MSC therapy 
      improves a variety of parameters in NIDCM irrespective of patient sex. These 
      findings have important clinical and pathophysiologic implications regarding the 
      impact of sex on responses to cell-based therapy for NIDCM.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. (c) 
      The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
FAU - Florea, Victoria
AU  - Florea V
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Rieger, Angela C
AU  - Rieger AC
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Natsumeda, Makoto
AU  - Natsumeda M
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Tompkins, Bryon A
AU  - Tompkins BA
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
FAU - Banerjee, Monisha N
AU  - Banerjee MN
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
FAU - Schulman, Ivonne H
AU  - Schulman IH
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
FAU - Premer, Courtney
AU  - Premer C
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Khan, Aisha
AU  - Khan A
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Valasaki, Krystalenia
AU  - Valasaki K
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
FAU - Heidecker, Bettina
AU  - Heidecker B
AD  - Department of Cardiology, Charite Berlin University of Medicine, Berlin, Germany.
FAU - Mantero, Alejandro
AU  - Mantero A
AD  - Department of Public Health Sciences, University of Miami Miller School of 
      Medicine, Miami, FL, USA.
FAU - Balkan, Wayne
AU  - Balkan W
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
FAU - Mitrani, Raul D
AU  - Mitrani RD
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
FAU - Hare, Joshua M
AU  - Hare JM
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Biomedical Research Building - 9th Floor 1501 NW 10th Ave, Miami, FL 
      33136, USA.
AD  - Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 
      USA.
LA  - eng
GR  - R01 HL110737/HL/NHLBI NIH HHS/United States
GR  - R01 HL137355/HL/NHLBI NIH HHS/United States
GR  - UL1 TR002736/TR/NCATS NIH HHS/United States
GR  - UM1 HL113460/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Biomarkers)
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Dilated/blood/pathology/physiopathology/*surgery
MH  - Endothelial Progenitor Cells/metabolism/pathology
MH  - Exercise Tolerance
MH  - Female
MH  - Florida
MH  - Functional Status
MH  - Health Status Disparities
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects
MH  - Middle Aged
MH  - Quality of Life
MH  - Recovery of Function
MH  - Sex Factors
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Ventricular Function, Left
MH  - Ventricular Remodeling
PMC - PMC7584465
OTO - NOTNLM
OT  - Cell therapy
OT  - Dilated cardiomyopathy
OT  - Heart failure
OT  - Mesenchymal stem cells
OT  - Sex
EDAT- 2020/02/14 06:00
MHDA- 2021/08/24 06:00
PMCR- 2021/02/13
CRDT- 2020/02/14 06:00
PHST- 2018/11/05 00:00 [received]
PHST- 2019/10/31 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/02/14 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/02/14 06:00 [entrez]
PHST- 2021/02/13 00:00 [pmc-release]
AID - 5735457 [pii]
AID - cvaa004 [pii]
AID - 10.1093/cvr/cvaa004 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2020 Nov 1;116(13):2131-2141. doi: 10.1093/cvr/cvaa004.